Based on the points we have outlined above, it is our opinion that treatment of stage II melanoma with BRAF inhibitors in the absence of data from suitable prognostic biomarkers that adequately predict the outcome of stage II melanomas, could lead to adverse outcomes for these patients. This evidence concerns the gene BRAF and melanoma.